Abstract:Background Congenital heart disease (CHD) represents a significant contributor to both morbidity and mortality in neonates and children. The prompt recognition of CHD can facilitate timely and appropriate intervention, reducing the probability of complications and enhancing the prognosis for impacted newborns. However, unlike other rare conditions routinely identified through federal and state newborn screening (NBS) programs, there’s currently no analogous dried blood spot (DBS) screening for CHD immediately after birth. Objective This study was set to identify reliable metabolite biomarkers with clinical relevance, with the aim to assess feasibility of screening and subtype classification of CHD utilizing the DBS newborn screening method. Methods We assembled a cohort of DBS datasets from the California Department of Public Health (CDPH) Biobank, encompassing both normal controls and three pre-defined CHD categories (tetralogy of Fallot, inherited arrhythmia syndrome, neonatal cardiomyopathy). A robust, DBS-oriented metabolomic method, employing both global and targeted strategies based on liquid chromatography with tandem mass spectrometry (LC-MS/MS), was developed. To verify the reliability of this metabolic profiling, we conducted a correlation analysis comparing the absolute quantitated metabolite concentration in DBS against the CDPH NBS records. Additionally, for hydrophilic and hydrophobic metabolites, we executed significant pathway and metabolite analyses respectively. Finally, logistic and LightGBM models were established to aid in CHD discrimination and classification. Results Our metabolomic workflow demonstrated consistent and reliable quantification of metabolites in DBS samples stored at the California Department of Public Health (CDPH) for up to 15 years. Through this process, we discerned dysregulated metabolic pathways in CHD patients, including deviations in lipid and energy metabolism, as well as oxidative stress pathways. Furthermore, we identified three metabolites as potential biomarkers for CHD assessment, and an additional twelve metabolites as potential markers for classifying different CHD subtypes within DBS samples. Conclusions This study represents the first attempt to validate metabolite profiling results using long-term storage DBS samples procured from the high-quality conditions of the CDPH biobank. The results unveil distinct metabolic discrepancies between various CHD subtypes and healthy controls. Furthermore, our findings highlight the potential clinical applications of our DBS-based methods for CHD screening and subtype classification. ### Competing Interest Statement K.J. Su, Q. Tang, J. Schilling, B. Jin are staff members of mProbe Inc. The rest of the authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. ### Funding Statement This study did not receive any funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of Stanford University gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors <http://translationalmedicine.stanford.edu>

Development of a fast and robust liquid chromatography-mass spectrometry-based metabolomics analysis method for neonatal dried blood spots

Effects of physical and chemical factors in environment for dried blood spot preparation of neonatal screening assay

[Screening for neonatal inborn errors of metabolism by electrospray ionization-tandem mass spectrometry and follow-up].

Current Problems and Prospect on Tandem Mass Spectrometry Based Newborn Inherited Metabolic Diseases Screening

Harmonization of distributed multi‐center analysis based on dried blood spot reference materials supporting the screening of neonatal inherited metabolic disorders

A Metabolic Biomarker Panel for Congenital Heart Disease Assessment with Newborn Dried Blood Spots

Development and performance of an analytical method for polychlorinated naphthalenes and other persistent organic pollutants in dried blood spots

From "wet" matrices to "dry" blood spot sampling strategy: a versatile LC-MS/MS assay for simultaneous monitoring caffeine and its three primary metabolites in preterm infants

Dried blood spots-based metabolomic analysis in preterm infants with necrotizing enterocolitis

Second-tier test for quantification of underivatized amino acids in dry blood spot for metabolic diseases in newborn screening

Exploratory Untargeted Metabolomics of Dried Blood Spot Samples from Newborns with Maple Syrup Urine Disease

Metabolite Stability in Archived Neonatal Dried Blood Spots Used for Epidemiologic Research

Targeted Metabolomics Reveals Birth Screening Biomarkers for Biliary Atresia in Dried Blood Spots

Quantification of trimethylsilyl derivatives of amino acid disease biomarkers in neonatal blood samples by gas chromatography-mass spectrometry

Determination of amino acid metabolic diseases from dried blood spots with a rapid extraction method coupled with nanoelectrospray ionization mass spectrometry

Application of liquid chromatography tandem mass spectrometry method from dry blood spots for the screening of inherited metabolic disease

Optimized DNA extraction from neonatal dried blood spots: application in methylome profiling

Multi-omics analysis from archival neonatal dried blood spots: limitations and opportunities

Reference Standards for Newborn Screening of Metabolic Disorders by Tandem Mass Spectrometry: A Nationwide Study on Millions of Chinese Neonatal Populations

Investigation of newborn blood metabolomics in varying intrauterine growth conditions

Analysis of Polychlorinated Biphenyls and Organochlorine Pesticides in Archived Dried Blood Spots and Its Application to Track Temporal Trends of Environmental Chemicals in Newborns.